Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
733 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Breast Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Breast Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Breast Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Metastatic Breast Cancer Overview 8 Therapeutics Development 9 Metastatic Breast Cancer - Therapeutics under Development by Companies 11 Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 20 Metastatic Breast Cancer - Pipeline Products Glance 22 Metastatic Breast Cancer - Products under Development by Companies 26 Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 38 Metastatic Breast Cancer - Companies Involved in Therapeutics Development 39 Metastatic Breast Cancer - Therapeutics Assessment 138 Drug Profiles 155 Metastatic Breast Cancer - Recent Pipeline Updates 515 Metastatic Breast Cancer - Dormant Projects 691 Metastatic Breast Cancer - Discontinued Products 700 Metastatic Breast Cancer - Product Development Milestones 704 Appendix 713
List of Tables Number of Products under Development for Metastatic Breast Cancer, H2 2014 28 Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2014 29 Number of Products under Development by Companies, H2 2014 31 Number of Products under Development by Companies, H2 2014 (Contd..1) 32 Number of Products under Development by Companies, H2 2014 (Contd..2) 33 Number of Products under Development by Companies, H2 2014 (Contd..3) 34 Number of Products under Development by Companies, H2 2014 (Contd..4) 35 Number of Products under Development by Companies, H2 2014 (Contd..5) 36 Number of Products under Development by Companies, H2 2014 (Contd..6) 37 Number of Products under Development by Companies, H2 2014 (Contd..7) 38 Number of Products under Investigation by Universities/Institutes, H2 2014 40 Comparative Analysis by Late Stage Development, H2 2014 41 Comparative Analysis by Clinical Stage Development, H2 2014 42 Comparative Analysis by Early Stage Development, H2 2014 43 Comparative Analysis by Unknown Stage Development, H2 2014 44 Products under Development by Companies, H2 2014 45 Products under Development by Companies, H2 2014 (Contd..1) 46 Products under Development by Companies, H2 2014 (Contd..2) 47 Products under Development by Companies, H2 2014 (Contd..3) 48 Products under Development by Companies, H2 2014 (Contd..4) 49 Products under Development by Companies, H2 2014 (Contd..5) 50 Products under Development by Companies, H2 2014 (Contd..6) 51 Products under Development by Companies, H2 2014 (Contd..7) 52 Products under Development by Companies, H2 2014 (Contd..8) 53 Products under Development by Companies, H2 2014 (Contd..9) 54 Products under Development by Companies, H2 2014 (Contd..10) 55 Products under Development by Companies, H2 2014 (Contd..11) 56 Products under Investigation by Universities/Institutes, H2 2014 57 Metastatic Breast Cancer - Pipeline by AbbVie Inc., H2 2014 58 Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H2 2014 59 Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 60 Metastatic Breast Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 61 Metastatic Breast Cancer - Pipeline by AlphaVax, Inc., H2 2014 62 Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2014 63 Metastatic Breast Cancer - Pipeline by Amgen Inc., H2 2014 64 Metastatic Breast Cancer - Pipeline by AngioGenex, Inc., H2 2014 65 Metastatic Breast Cancer - Pipeline by Aphios Corporation, H2 2014 66 Metastatic Breast Cancer - Pipeline by Array BioPharma Inc., H2 2014 67 Metastatic Breast Cancer - Pipeline by AstraZeneca PLC, H2 2014 68 Metastatic Breast Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 69 Metastatic Breast Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 70 Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2014 71 Metastatic Breast Cancer - Pipeline by BIOCAD, H2 2014 72 Metastatic Breast Cancer - Pipeline by Biocon Limited, H2 2014 73 Metastatic Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 74 Metastatic Breast Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2014 75 Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 76 Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 77 Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2014 78 Metastatic Breast Cancer - Pipeline by Celgene Corporation, H2 2014 79 Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 80 Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H2 2014 81 Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2014 82 Metastatic Breast Cancer - Pipeline by CTI BioPharma Corp., H2 2014 83 Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2014 84 Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 85 Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 86 Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H2 2014 87 Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2014 88 Metastatic Breast Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 89 Metastatic Breast Cancer - Pipeline by Etubics Corporation, H2 2014 90 Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 91 Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H2 2014 92 Metastatic Breast Cancer - Pipeline by Genentech, Inc., H2 2014 93 Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2014 94 Metastatic Breast Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 95 Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2014 96 Metastatic Breast Cancer - Pipeline by GTx, Inc., H2 2014 97 Metastatic Breast Cancer - Pipeline by Hospira, Inc., H2 2014 98 Metastatic Breast Cancer - Pipeline by Immune Design Corp., H2 2014 99 Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H2 2014 100 Metastatic Breast Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 101 Metastatic Breast Cancer - Pipeline by Immutep S.A., H2 2014 102 Metastatic Breast Cancer - Pipeline by Imugene Limited, H2 2014 103 Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 104 Metastatic Breast Cancer - Pipeline by Incyte Corporation, H2 2014 105 Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 106 Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2014 107 Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 108 Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2014 109 Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 110 Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2014 111 Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H2 2014 112 Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H2 2014 113 Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H2 2014 114 Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 115 Metastatic Breast Cancer - Pipeline by Merus B.V., H2 2014 116 Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H2 2014 117 Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 118 Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H2 2014 119 Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2014 120 Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H2 2014 121 Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2014 122 Metastatic Breast Cancer - Pipeline by Neopharm Ltd., H2 2014 123 Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 124 Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 125 Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 126 Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2014 127 Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 128 Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H2 2014 129 Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 130 Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 131 Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2014 132 Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 133 Metastatic Breast Cancer - Pipeline by Pfizer Inc., H2 2014 134 Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H2 2014 135 Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H2 2014 136 Metastatic Breast Cancer - Pipeline by Polaris Group, H2 2014 137 Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H2 2014 138 Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H2 2014 139 Metastatic Breast Cancer - Pipeline by Recombio S.L, H2 2014 140 Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H2 2014 141 Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2014 142 Metastatic Breast Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 143 Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H2 2014 144 Metastatic Breast Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 145 Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 146 Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 147 Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H2 2014 148 Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H2 2014 149 Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2014 150 Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 151 Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2014 152 Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2014 153 Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 154 Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H2 2014 155 Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H2 2014 156 Assessment by Monotherapy Products, H2 2014 157 Assessment by Combination Products, H2 2014 158 Number of Products by Stage and Target, H2 2014 160 Number of Products by Stage and Mechanism of Action, H2 2014 166 Number of Products by Stage and Route of Administration, H2 2014 171 Number of Products by Stage and Molecule Type, H2 2014 173 Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H2 2014 534 Metastatic Breast Cancer - Dormant Projects, H2 2014 710 Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2014 711 Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2014 712 Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2014 713 Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2014 714 Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2014 715 Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2014 716 Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2014 717 Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2014 718 Metastatic Breast Cancer - Discontinued Products, H2 2014 719 Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2014 720 Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2014 721 Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2014 722
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
